Merck (MRK) Tops Q4 EPS by 1c, Offers FY Guidance

Merck (NYSE: MRK) reported Q4 EPS of $1.16, $0.01 better than the analyst estimate of $1.15. Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.98 billion.

GUIDANCE:

Merck sees FY2020 EPS of $5.62-$5.77, versus the consensus of $5.61. Merck sees FY2020 revenue of $48.8-50.3 billion, versus the consensus of $49.53 billion.

• At mid-January 2020 exchange rates, Merck anticipates full-year 2020 revenue to be between $48.8 billion and $50.3 billion, including a negative impact from foreign exchange of less than 1%.
• Merck expects full-year 2020 GAAP EPS to be between $4.57 and $4.72. Merck expects full-year 2020 non-GAAP EPS to be between $5.62 and $5.77, including an approximately 1.5% negative impact from foreign exchange. The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c